Evogene (NASDAQ: EVGN; TASE: EVGN) and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have announced a collaboration that aims to expedite the development of small-molecule drug discovery originating from Israeli academic research.
The agreement will combine computational and experimental tools for academic teams and scientific entrepreneurs seeking to advance early-stage drug candidates. The partnership will provide a framework connecting Evogene’s AI-based computational chemistry engine, ChemPass AI, with the BCDD’s laboratory infrastructure and translational expertise.
In a statement, Ofer Haviv, president and CEO of Evogene, commented, “Israel’s academic institutions generate world-class discoveries and novel therapeutic targets. However, many entrepreneurs and researchers face significant hurdles in transforming these scientific insights into viable drug development programs. Through this collaboration with the Blavatnik Center for Drug Discovery, we are creating a unique framework that combines advanced AI-driven computational chemistry with world-class experimental validation capabilities. This collaboration represents an excellent way to broaden the pipeline of drug candidates developed by Evogene’s unique technology.”
He added, “Researchers focused on biological targets, particularly molecular glues and complex proteins, and interested in identifying small-molecule therapeutics are invited to contact the Blavatnik Institute. We look forward to identifying suitable projects for potential joint support.”
